University of Groningen

PCSK9 and syndecan-1 in renal disease-related dyslipidemia

Shrestha, Pragy

DOI:
[10.33612/diss.201998315](https://doi.org/10.33612/diss.201998315)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Shrestha, P. (2022). *PCSK9 and syndecan-1 in renal disease-related dyslipidemia*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.201998315>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

PCSK9 and syndecan-1 in renal disease-related dyslipidemia

Pragyi Shrestha

Different parts of this PhD project were financially supported by: University Medical Center Groningen; Graduate School of Medical Sciences (GSMS); Jan Kornelis De Cock Stichting; CNRS and the GDR GAG (GDR 3739), the “Investissements d’avenir” program Glyco@Alps (ANR-15-IDEX-02); Agence Nationale de la Recherche (ANR-17-CE11-0040); IBS acknowledges integration into the Interdisciplinary Research Institute of Grenoble (IRIG, CEA); AbbVie.

The printing of this thesis was financially supported by: University Medical Center Groningen; Graduate School of Medical Sciences (GSMS) and Rijksuniversiteit Groningen (RUG).

Author: Pragyi Shrestha

Cover design: Dr. Marines Du Teil

Layout design: Dr. Bimal Prajapati

Nepali Summary: Er. Purna Kumar Shrestha

Printed by: Ipskamp Printing

Dissertation University of Groningen, the Netherlands

ISBN/EAN: 978-94-6421-662-2

©Copyright 2022 Shrestha P, the Netherlands

All right reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior permission of the author.

university of
 groningen

PCSK9 and syndecan -1 in renal disease-related dyslipidemia

PhD thesis

to obtain the degree of PhD at the
University of Groningen
on the authority of the
Rector Magnificus Prof. C. Wijmenga
and in accordance with
the decision by the College of Deans.

This thesis will be defended in public on

Wednesday 2 March 2022 at 11.00 hours

by

Pragyi Shrestha

born on 13 September 1990
in Kathmandu, Nepal

Supervisors

Prof. J. van den Born

Prof. A.J.A. van de Sluis

Assessment Committee

Prof. J.A. Kuivenhoven

Prof. J. van der Vlag

Prof. S.P. Berger

Paranymphs

Dr. Samiksha Ghimire

Dr. Bimal Prajapati

Alan Ray Gorter

This thesis is dedicated to my mom and dad.

यो थेसिस मेरो आमा र बाबालाई समर्पित छ।

CONTENTS

Chapter 1	General Introduction	11
Chapter 2	Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia	31
Chapter 3	Proteinuria converts hepatic heparan sulfate proteoglycans to effective PCSK9 binding partner	71
Chapter 4	Hypercholesterolemia in progressive renal failure associates with changes in hepatic heparan sulfate-PCSK9 interaction	113
Chapter 5	Prevention of triglyceridemia by (non-)anticoagulant heparin(oids) does not preclude transplant vasculopathy and glomerulosclerosis	159
Chapter 6	Improvement of albuminuria by the endothelin receptor antagonist atrasentan correlates to PCSK9 reduction in type 2 diabetic nephropathy patients	191
Chapter 7	Final Discussion and Future Perspectives	205
Appendices	Summary	227
	Nederlandse samenvatting	231
	Nepali summary	233
	Acknowledgments	235
	Biography	247
	List of Publications	249